While biosimilars approved by regulators have been shown to have no clinically meaningful differences from their reference products, this week, during the San Antonio Breast Cancer Symposium, held in San Antonio, Texas, researchers will report reassuring data for biosimilar trastuzumab, Ogivri, showing that the combination of the biosimilar with pertuzumab is highly similar to the combination of the reference drug with pertuzumab.
Trastuzumab, used in the treatment of HER2-positive breast cancer, is given in some regimens together with pertuzumab to improve clinical benefit; the 2 antibodies bind to HER2 at different subdomains and have a synergistic effect. Biosimilar trastuzumab has also made combination trastuzumab/pertuzumab treatment more affordable, allowing greater patient access.
While biosimilars approved by regulators have been shown to have no clinically meaningful differences from their reference products, this week, during the San Antonio Breast Cancer Symposium, held in San Antonio, Texas, researchers will report reassuring data for biosimilar trastuzumab, Ogivri, showing that the combination of the biosimilar with pertuzumab is highly similar to the combination of the reference drug with pertuzumab.
In the study, researchers used 2 cancer cell lines, BT474 and HCC1954, to perform all tests. Fluorescence-activated cell sorting—based antigen binding evaluations and live cell imaging were performed for the reference trastuzumab, the biosimilar, and pertuzumab in combinations at concentrations of 0, 10, 100, and 1000 ng/mL.
Predefined acceptance criteria for the ligand-binding assay (LBA) was ±20%. Proliferation and CDC complement-dependent cytotoxicity (CDC) assays for the reference and biosimilar trastuzumab were tested at concentrations of 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, and 100 mcg/mL in combination with pertuzumab at concentrations of 1, 10, and 100 mcg/mL; the number of viable cells was also estimated. Equivalence was stablished if the 90% CI of the difference between means fell within ±20%.
In the BT474 cell line:
In the HCC1954 cell line:
According to the authors, these results show that biological activity showed the same patterns in the presence of both reference and biosimilar trastuzumab in combination with pertuzumab, and that the combinations are highly similar.
Reference
Pimentel FF, Toledo JS, Gonçalves J, et al. Comparative evaluation of a trastuzumab biosimilar or originator trastuzumab in association with pertuzumab: binding and biological activities in cell culture-based assays. Presented at: San Antonio Breast Cancer Symposium, December 10-14, 2019; San Antonio, TX. Abstract P5-05-08.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Achieving PFS in Advanced Gastric Cancer With HLX02 Biosimilar, Chemotherapy
November 23rd 2024In a phase 2 study, the addition of HLX22, an anti-HER2 antibody, to HLX02 biosimilar and XELOX (oxaliplatin and capecitabine) chemotherapy extended progression-free survival (PFS) in untreated HER2-positive advanced gastric cancer patients.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.